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Cancer Therapy

Current therapies for glioblastoma are largely palliative, involving surgical resection followed by chemotherapy and radiation
therapy, which yield serious side effects and very rarely produce complete recovery. Curcumin, a food component, blocked
brain tumor formation but failed to eliminate established brain tumors in vivo, probably because of its poor bioavailability. In
the glioblastoma GL261 cells, it suppressed the tumor-promoting proteins NF-jB, P-Akt1, vascular endothelial growth factor,
cyclin D1 and BClXL and triggered cell death. Expression of exogenous p50 and p65 subunits of NF-jB conferred partial protection on transfected GL261 cells against curcumin insult, indicating that NF-jB played a key role in protecting glioblastoma
cells. To enhance delivery, we coupled curcumin to the glioblastoma-specific CD68 antibody in a releasable form. This resulted
in a 120-fold increase in its efficacy to eliminate GL261 cells. A very similar dose response was also obtained with human
glioblastoma lines T98G and U87MG. GL261-implanted mice receiving intratumor infusions of the curcumin-CD68 adduct followed by tail-vein injections of solubilized curcumin displayed a fourfold to fivefold reduction in brain tumor load, survived
longer, and about 10% of them lived beyond 100 days. Hematoxylin–eosin staining of brain sections revealed a small scar tissue mass in the rescued mice, indicating adduct-mediated elimination of glioblastoma tumor. The tumor cells were strongly
CD681 and some cells in the tumor periphery were strongly positive for microglial Iba1, but weakly positive for CD68. This
strategy of antibody targeting of curcumin to tumor comes with the promise of yielding a highly effective therapy for glioblastoma brain tumors.

Glioblastoma is one of the most aggressive and deadly forms
of cancers affecting the nervous system. Prognosis remains
very poor, as anticancer agents have difﬁculty crossing the
blood–brain barrier and tumor cells are resistant to standard
therapies. Even with surgery, radiation and chemotherapies,
treatment remains only palliative. Surprisingly, the highest
incidence rate of this type of cancers is observed in the
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industrially developed countries of the world.1,2 Welldesigned epidemiological studies, especially one performed in
China, have strongly related this observation to lifestyle and
intake of large quantities of processed meat and animal
protein.2,3
Although the recent focus on personalized therapy has led
to massive, technically sophisticated and expensive analyses
of the genetic proﬁles of cancer patients, the fact that most
cancer cells display some common features and molecular
characteristics that can be targeted by harmless natural agents
has been largely ignored. For example, epidemiological studies have clearly shown that colon cancer is virtually absent in
the Southeast Asian countries where the powerful anticancer
agent turmeric is consumed in large quantities in a regular
diet as a culinary spice.4–7 Furthermore, it has also been
demonstrated that the coloring component of turmeric curcumin is highly potent in eliminating a large variety of cancer cell types without damaging normal tissue.4,7,8 Although
very promising in preclinical studies, the efﬁcacy of curcumin
in human trials has been limited. This in part is due to curcumin’s low solubility in water causing poor systemic bioavailability and rapid clearance. We have shown that this
difﬁculty can be overcome by synthetic linkage of curcumin
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What’s new?
Curcumin, the most active ingredient of the yellow spice turmeric traditionally used in Indian cuisine, has known antitumor
activities. However, its low bioavailability is a major obstacle to its use in cancer therapy. Here the authors tested the efficacy
of curcumin in cell culture and mouse models of glioblastoma, a highly treatment-resistant brain cancer. Curcumin was reversibly coupled to the glioblastoma-specific CD68 antibody, which resulted in a markedly increased efficacy to eliminate glioblastoma cells in vivo. The study raises hope that with the appropriate targeting curcumin may rise to a new anti-brain cancer
agent in the future.

Material and Methods
See Supporting Information for further details.
Animals

Adult C57BL/6 male mice (2–6 months old) were used for
the experiments. Animals were bred in the College of Staten
Island (CSI) Animal Care Facility and maintained on a 12-hr
light/dark cycle with ad libitum access to food and water. All
animals were handled and used for surgery following an
experimental protocol approved by the Institutional Animal
Care Committee (IACUC) of the College of Staten Island
(CUNY).

C 2013 UICC
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Reagents, antibodies and cell lines

See Supporting Information for details.
Synthesis of curcumin carboxylate NHS ester; 2,5-dioxycyclopentyl 4-((1E,6E)27-(4-hydroxy-3-methoxyphenyl)23,5-dioxohepta-1,6-dienyl)22-methoxyphenyl glutarate. The curcumin

NHS ester was synthesized as described in detail in our earlier publications.9,12,13
Cell culture

GL261 mouse glioblastoma cells and the human glioblastoma
U87MG and T98G cells were cultured in RPMI 1640 containing 10% (v/v) FBS (fetal bovine serum) and 1% (v/v)
penicillin–streptomycin (Pen-Strep) with 2 mM glutamine
and 2 mM glutamax. Before and during drug treatment, the
cells were placed in neurobasal medium containing 2% (v/v)
B-27 supplement and 1% (v/v) Pen-Strep.
Preparation of curcumin-CD68 Ab and Dylight 800-CD68
Ab adducts

Curcumin was coupled to the CD68 antibody according to
reported procedures by adding tenfold molar excess of succinimidyl curcumin carboxylate (curcumin-NHS ester) dissolved in
dimethylsulfoxide (DMSO, 10% v/v) to CD68 antibody (20 mg)
in 50 mM sodium bicarbonate buffer (pH 8.3).14 After the coupling reaction between the curcumin-NHS ester and the CD68
antibody, the adduct (CDC) was puriﬁed using a spin column.
The curcumin:Ab ratio was determined by spectroscopy and
also by MALDI-TOF (Supporting Information Fig. 1).9,15 (Further details have been included in Supporting Information.)
Determination of IC50

GL261 cells (2,000 per well) were grown for 24 hr in a 96well plate and then curcumin or curcumin-CD68 Ab treatment at indicated concentrations was performed in triplicate
wells for 24–48 hr in serum-free neurobasal medium (with
2% B27 and 1% Pen-Strep).8 Live cells were counted in six or
more randomly chosen ﬁelds per well to obtain mean count
per ﬁeld of view.
In some experiments, subsequent to free curcumin or
curcumin-Ab adduct treatment in triplicate wells, 10% by
volume of WST-1 (Clontech, Mountain View, CA) was added
to each well followed by incubation at 37 C for 2 hr and
measurement of absorbance at 440 nm. Results obtained
from two experiments performed with triplicate samples were
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to an antibody for enhanced tissue delivery.9 Antibody drug
conjugates traditionally attempt to selectively deliver cytotoxic
drugs to tumors. However, signiﬁcant adverse effects are
encountered from off-target release of the toxin. Gemtuzumab
ozogamicin, an FDA-approved anti-CD33 drug conjugate
(MylotargTM) for the treatment of acute myeloid leukemia,
was withdrawn from the market because of its toxicity.10
Attempts to increase efﬁcacy by concentrating compounds
derived from dietary or medicinal plants into tumor tissue
have been received with concern and deemed similar to
antibody-targeted toxic agents like Mylotarg. We emphasize
that antibody-mediated targeting does not have to only carry
toxic chemotherapeutic agents to speciﬁc cancer cells. Rather,
it can be used to enhance the delivery of potent natural anticancer agents like curcumin, which cannot be otherwise used
to combat established cancers because of issues related to
poor systemic bioavailability.
Using this concept and a carefully crafted scheme of
targeting curcumin to melanoma cells, we have already
shown that our strategy is highly effective in rescuing mice
with established, melanoma-evoked brain tumors.9 Our study
uses a similar scheme in which we create a CD68 antibody–
curcumin conjugate (CDC) that is highly speciﬁc and effective in eliminating two human glioblastoma cell lines in vitro.
Our in vivo model, created by intracranially implanting
mouse glioblastoma cancer cells (GL261), shows CDCmediated shrinkage of established glioblastoma brain tumors.
This increases the longevity of the mice and completely rescues some of the animals. Like in the melanoma cells, the
primary target of curcumin in the glioblastoma GL261 cells
appears to be NF-jB, which is dramatically upregulated in a
large number of cancer cells.11

Cancer Therapy
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Figure 1. NF-jB could be the primary target of curcumin in the GL261 cells. (a) The expression levels of NF-jB, Akt-1, VEGF, cyclin D1 and
BCLXL normalized to the corresponding b-actin levels were significantly reduced after curcumin (50 mM) treatment for 24 hr. Student’s t-test
p values: 0.028778 (NF-jB), 0.041 (pNF-jB), 0.048 (BclXL), 0.044654 (Akt), 0.038 (pAkt), 0.043 (VEGF), 0.100 (Erk 1/2), 0.181 (pErk 1/2),
0.252 (c-Myc), 0.015 (cyclin D1) and 0.953 (HSP70). Curcumin (50 mM) treatment for 8 hr does not cause morphological degeneration (Supporting Information Fig. 2a), but elicits rapid inhibition of NF-jB expression (b). (c) Expression of exogenous NF-jB subunits p50 and p65
in GL261 cells causes induced expression of luciferase from a NF-jB-luciferase reporter construct. (d) Exogenous NF-jB partially rescues
the cells from death caused by 96 hr of curcumin (6.25 and 12.5 mM) treatment (measured by WST-1 assay) (p < 0.5; t-test).

analyzed using t-test (two-tailed distribution, two-sample
unequal variance).
Immunostaining of GL261, U87MG and T98G cells

Attached cells in the wells were rinsed with 10 mM
phosphate-buffered saline (PBS), ﬁxed in 4% paraformaldehyde, rinsed thrice with PBS, blocked in 10% goat serum in

PBS plus 0.1% Triton X-100 and then immunostained using
a CD68 Ab (sc-9139, which recognizes both mouse and
human CD68) (1:200) and a secondary antibody (Alexa Fluor
568 goat anti-rabbit) (1:1,000). CD68 Ab-stained images were
acquired from random ﬁelds with a Zeiss Axio Observer Z1
microscope and an AxioVision 4.6.3-AP1 camera at excitation wavelength of 488 nm.
C 2013 UICC
Int. J. Cancer: 135, 710–719 (2014) V
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Caspase3/7 assay

This assay was performed as described earlier.8 Statistical
analysis was performed using Student’s t-test or ANOVA
with Bonferroni post hoc tests.
Implantation of cancer cells in mice and intracranial drug
infusion16

(H-255) (green), goat anti-rat
RM0029-11H3 (red) and rabbit
Iba1 (far red). Confocal images
SP2 AOBS confocal microscope
berg, Germany). Further details
porting Information.

phycoerythrin (sc3740) for
anti-goat Alexaﬂuor 633 for
were acquired using a Leica
(Leica Microsystems, Heidelhave been included in Sup-

See Supporting Information for details.

Results

Hematoxylin–eosin staining of tissue sections

Curcumin treatment causes a dramatic inhibition in the
levels of NF-jB, Akt-1, vascular endothelial growth factor,
cyclin D1 and BClXL

The ﬁxed brains were cryosectioned and hematoxylin–eosin
(H&E) stained according to our earlier report.8
Immunohistochemistry

Coronal sections (30 mm) were made from 4%
paraformaldehyde-ﬁxed and 30% sucrose-soaked mouse brains
harboring glioblastoma tumors. Sections containing tumor tissue were chosen and subjected to immunohistochemistry using
CD68, Iba1 (microglia/macrophage)17 and RM0029-11H3
(macrophage)18 antibodies, each at 1:50 dilution. The secondary antibodies were goat anti-rabbit Alexaﬂour 488 for CD68
C 2013 UICC
Int. J. Cancer: 135, 710–719 (2014) V

The mouse GL261 glioblastoma cells were treated with carrier
or curcumin (50 mM) for 24 hr. Western blot analysis of
lysates prepared from the post-treatment cells revealed that
both NF-jB as well as its activated version, phospho-NF-jB,
were suppressed in a dramatic manner (Fig. 1). In our earlier
studies, activated NF-jB stimulated Akt-1 in the B16F10
cells.9 In the GL261 cells, both expression and activation levels of Akt-1 (shown by the levels of phospho-Akt-1) were
inhibited in a dramatic manner by curcumin (Fig. 1a). In
addition, we also observed that the levels of BClXL, an

Cancer Therapy

Figure 2. CD68 is expressed by both human and mouse glioblastoma cells and a CD68 Ab shows dramatically lower binding to normal
brain tissue. (a–c) In each case an Alexafluor488-linked (green) anti-mouse 2 antibody was used. Nuclei were stained using DAPI (blue).
The green frame (left) and blue frame (right) have been juxtaposed to show the presence or absence of staining with the CD68 Ab or the
2 Ab alone. (d and g) GL261 (105) cells were implanted in the right forebrain on Day 1 and CD68 Ab-Dylight800 (CD68Dy) infused into the
same site on Day 21, and after 24 hr, the mice were sacrificed and brains extricated for imaging using near-IR scanning. (e) Brightfield
image of the brain shown in (d) demonstrating colocalization of the tumor with the CD68Dy stain. (f) H&E staining of brain section from
another brain confirms the presence of tumor (black arrows). (g) CD68Dy infused at the original site of BL261 implantation on right (yellow
arrow) diffuses and binds to tumor on left. (h) Brightfield image of brain shown in (g) confirms colocalization of tumor with CD68Dy labeling
(green) (black arrow). (i) The status of the tumor at Day 8 after GL261 implantation. (j) Similar infusion of CD68Dy into the right forebrain
of a tumor-na€ıve mouse followed by imaging after 24 hr shows no CD68Dy labeling. [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
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inhibitor of apoptosis, cyclin D1, a cell cycle promoter, and
vascular endothelial growth factor (VEGF), a promoter of
angiogenesis, were suppressed signiﬁcantly. However, curcumin did not signiﬁcantly affect the expression of c-Myc,
HSP70, Erk1/2 and pErk1/2 (Fig. 1a).
We expected that the primary target of curcumin would
be most rapidly regulated even before the cells show any sign
of degeneration. We observed no sign of degeneration of
GL261 cells upon treatment with 50 mM of curcumin for 8
hr (Supporting Information Fig. 2a), but this treatment was
sufﬁcient to cause a dramatic suppression of NF-jB synthesis
(Fig. 1b). To test the involvement of NF-jB in curcuminevoked GL261 death, we ﬁrst overexpressed the p50 and p65
subunits of NF-jB along with a luciferase reporter vector
driven by an NF-jB-inducible promoter to demonstrate
increased expression of NF-jB in the transfected cells 24 hr
post-transfection (Fig. 1c). Twenty hours after transfection,
these cells were treated with curcumin at indicated concentrations to observe partial reversal of curcumin-evoked viability in GL261 cells expressing exogenous p50 and p65
subunits of NF-jB (Fig. 1d).

Cancer Therapy

Mouse glioblastoma (GL261) as well as human
glioblastoma (T98G and U87MG) cells express high levels
of CD68

Although curcumin has a strong cytotoxic activity toward a
wide range of cancer cells,8 treatment of established brain
tumors with implanted melanoma cells is not eliminated by
curcumin treatment alone.8 Subsequently, we had shown that
covalent linking of curcumin to a cancer cell-speciﬁc antibody dramatically increased its anticancer potency against
melanoma cells.9 To use the same strategy, we looked for an
antigen that showed dramatically higher expression on the
surface of glioblastoma cells than the other brain cells. CD68
is a 110-kDa transmembrane glycoprotein that is expressed
by monocyte/macrophage lineages and reactive microglia also
express CD68.19 However, in malignant astrocytoma cells
CD68 positivity is known to be very high.20 As presented
below, we observed strong CD68 staining in the GL261
tumors and weak CD68 staining in Iba1(1) cells (microglia)
in the tumor periphery (Fig. 3). Furthermore, survival analysis has shown that CD68 tumor staining has prognostic value
for glioma patients, as high antigen expression is associated
with shorter survival.21 Therefore, differentially expressed
CD68 in brain tissue was an ideal target for our CDC.
As expected, immunocytochemical analysis revealed that
CD68 was highly expressed on GL261 as well as the human
glioblastoma cells U87MG and T98G in culture (Figs. 2a–2c).
To test the efﬁcacy of CD68 antibody-mediated targeting
to glioblastoma brain tumors, we covalently linked this antibody to the near-infrared dye Dylight800 (CD68Dy) and
intracranially infused CD68Dy into mice harboring glioblastoma generated by implanting 105 GL261 cells into the right
forebrain of mice. CD68Dy concentrated in the tumor after
24 hr regardless of its ﬁnal location in the right or left fore-
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brain (Figs. 2d and 2g). Even at Day 8 after implantation of
GL261 tumor cells, CD68Dy labels a small tumor in the
brain (Fig. 2i). In sharp contrast, similar infusion of CD68Dy
into the brain of tumor-na€ıve mice did not produce any
detectable labeling of normal brain cells (Fig. 2j). The location of the glioblastoma tumor was also detectable by brightﬁeld imaging (Figs. 2e and 2h) and histopathologic
examination using H&E staining (Fig. 2f).
The cells in the tumor show strong immunohistochemical
staining with CD68 antibody, and peripheral cells show
staining with Iba1 (microglia) antibody but not with
RM0029-11H3 (macrophage) antibody

Coronal sections of GL261 tumor-containing brain were prepared and consecutive sections containing the tumor were
analyzed for immunohistochemical staining with antibodies
against CD68 (Figs. 3a and 3b), Iba1 (microglia marker)
(Figs. 3c and 3d) and RM0029-11H3 (macrophage marker)
(Fig. 3e). Results shown in Figure 3 demonstrate high levels
of CD68 expression (green) of the tumor cells. Staining using
the microglia/macrophage-speciﬁc Iba1 antibody (red)
showed the presence of microglial cells in the tumor periphery (Figs. 3d and 3e), which were weakly CD681 (Fig. 3f, left
panel, green), but were not stained with the macrophagespeciﬁc RM0029-11H3 antibody (red) (Fig. 3c).
Attachment to CD68 antibody causes a 120-fold decrease
in the IC50 of curcumin

We covalently linked curcumin through a cleavable linkage
to the CD68 and veriﬁed that the antibody:curcumin ratio
was 1:1 (Supporting Information Fig. 1). Next, the GL261
cells were treated with carrier or various concentrations of
curcumin in one experiment and with CD68 antibody alone
(control) or various concentrations of CD68 antibody-linked
curcumin (CDC) in a second experiment. Cell viability was
measured by counting healthy cells and also by WST-1
assays. Although curcumin treatment alone yielded an IC50
of 15 mM (Figs. 4a–4d), treatment with the CD68 antibodyconjugated curcumin indexed an IC50 of 125 nM (Figs.
4f24h). Very little inhibition of the viability of normal
human ﬁbroblasts was observed even at much higher concentrations of curcumin (Fig. 4i). CDC also eliminated human
glioblastoma cells U87MG and T98G in the nanomolar range
of IC50 (400 and 225 nM, respectively) (Figs. 4k and 4m),
whereas the IC50 values for curcumin alone were 25 and 8
mM, respectively.
Curcumin fluorescence from CDC increases upon
internalization and causes destruction of GL261
glioblastoma cells within 2 hr of treatment

GL261 cells, cultured in a 96-well plate, were placed in
serum-free neurobasal medium with 1% B27 serum supplement and treated with 540 nM CDC and time-lapse photography was used both with and without ﬂuorescence
microscopy. The ﬂuorescence increased from dull to intense
C 2013 UICC
Int. J. Cancer: 135, 710–719 (2014) V
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Figure 3. The cells in the tumor show strong staining with CD68 antibody, and peripheral cells show staining with Iba1 (microglia) antibody,
and no staining with RM0029-11H3 (macrophage) antibody. (a and b) CD68 Ab (green) staining of tumor cells. (c) Tumor cells did not stain
with RM0029-11H3 (macrophage) Ab (far red). (d and e) Some cells in the tumor periphery stained with Iba1 Ab (microglia and macrophage).
(f) The peripheral cells were weakly stained with CD68 (green) and strongly stained with Iba1 (red). HOECHST33342 (blue) (nuclear staining).
(g–i) No nonspecific staining was observed with any of the 2 antibodies. Scale bars: (320) 129.64 mm; (363) 41.16 mm. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]

when some membrane-attached CDC molecules fused to two
cells, suggesting the release of free curcumin from the antibody owing to the action of intracellular esterases on the
linker portion of the antibody–drug complex (Supporting
Information Figs. 2b–2d). At this point brightﬁeld imaging
showed degradation of the cells (Supporting Information Fig.
2e). Complete morphological analysis with time-lapse imaging was also performed and at treatment, the cells appeared
healthy (Supporting Information Fig. 2f), but blebbing and
deformation of cells started within 45 min (Supporting Information Fig. 2g), and many cells released their internal contents (cell debris) within 2 hr (Supporting Information Fig.
2h). Upon treatment of GL261 cells with CDC for 24 hr a
dramatic increase in caspase-3/7 activity was also observed
(Supporting Information Fig. 2i).

C 2013 UICC
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C68 Ab-linked Dylight800 labels glioblastoma brain
tumors and targeted curcumin causes a major reduction in
tumor load and extends survival of glioblastoma-implanted
mice

GL261 cells (105) were implanted in the right forebrain of
each C57BL6 mouse on Day 1 and the mice were subjected
to intracranial infusion of CD68 antibody alone or CDC (16
pmol per infusion) twice on Days 13 and 15. This was followed by tail-vein infusion of curcumin (667 mM in PBS containing 0.125% DMSO), six times, once every week. This
treatment caused a major decrease in glioblastoma tumor
burden (Figs. 5a–5c) and prolonged the life of the mice signiﬁcantly (Fig. 5d). In a second set of experiments, eight
mice were used in each of two groups. The control group
received four intracranial infusions of 30 pmol of CD68 Ab

Cancer Therapy
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Figure 4. CD68 Ab-linked curcumin is 120 times more potent than curcumin alone in eliminating glioblastoma GL261 cells. (a–d) Effect of
solubilized curcumin on GL261 cells (IC50 5 15 mM). GL261 cells subjected to treatment with DMSO-solubilized curcumin (neurobasal/
DMSO < 0.2%) or neurobasal control for 24 hr. (e–h) Effect of curcumin adduct on GL261 cells (IC50 5 125 nM). Images of GL261 cells subjected to treatment with curcumin-CD68 adduct or CD68 control for 24 hr. Counting of viable cells and NADH oxidoreductase-based WST-1
assays9 yielded very similar results. (i) Curcumin treatment of normal human fibroblasts causes very little inhibition of cell viability at much
higher concentrations. (k and m) The CD68-linked curcumin eliminates human glioblastoma cells U87MG and T98G also in the nanomolar
range of IC50 (400 and 225 nM, respectively).

alone and the second group received four intratumor infusions of 30 pmol CDC per infusion per mouse from Day 8,
every 72 hr. Next, tail-vein infusion of curcumin (667 mM)
was performed ﬁrst every 72 hr (ﬁve times) and then once
per week (two times). This yielded a major increase in

longevity of the CDC-treated mice (Fig. 5g) and about 10%
of the treated mice survived beyond 90 days in each experiment. Although H&E staining of a control brain not receiving the adduct showed widespread degeneration due to
glioblastoma (Fig. 5e), of the mice that remained healthy and
C 2013 UICC
Int. J. Cancer: 135, 710–719 (2014) V
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normal, one was sacriﬁced 100 days after implantation of
GL261 cells. H&E staining of brain sections from this mouse
showed the presence of scar tissue at the original site of
tumor (Fig. 5f; enlarged view shown in Fig. 5h), but no apparent sign of any inﬂammation in the tissue. Additionally,
treatment with either curcumin8 or CDC did not produce
any inﬂammation or injury in the normal brain tissue of
mice after 72 hr of treatment (Langone et al., unpublished
data).

Discussion
Our report demonstrates that the glioblastoma-directed
CD68 antibody binds to human glioblastoma cells, labels
GL261-evoked mouse brain tumor, but does not label normal
brain tissue. Thus, this report presents a possible strategy of
potentiating the antitumor activity of a harmless food component curcumin by selectively targeting it to the glioblastoma brain tumor. Magnetic resonance imaging detection of
human brain tumors can be achieved even when the tumor
size is as little as 1.5 cm3,22 which constitutes about 0.1% of
the total brain volume of an adult human being (1,400 cm3).
Using near-IR imaging, we had observed earlier that B16F10
melanoma-evoked brain tumors grow very rapidly from the
time of intracranial implantation of tumor cells to assume
almost 10–20% of mouse brain volume (400 ml) after 8 days.9
In contrast, the GL261-evoked tumors grow slower, attaining
about 5% (i.e., about 20 ml) of total brain volume after
C 2013 UICC
Int. J. Cancer: 135, 710–719 (2014) V

8 days. Based on such estimation, the concentration of
antibody-linked curcumin achieved in the tumor after infusion of 30 pmol of CDC would be 1.5 mM. This was sufﬁcient to cause a major increase in longevity and complete
rescue in about 10% of the treated mice. However, our projected goal is to achieve a concentration of 4.5 mM or higher
for our antibody-linked curcumin, this is expected to achieve
much higher rates of remission. Our in vitro experiments
have demonstrated that a 720 nM concentration of CDC is
effective in eliminating glioblastoma cells. Allowing some loss
of adduct after intracranial infusion, 4.5 mM should be optimal to achieve a dramatically higher percentage of complete
recovery. The objective of our study was to validate the in
vivo efﬁcacy of our CDC as well as to test the speciﬁcity of
our CD68 target. Our data show that even at very low doses,
administration of our curcumin adduct has strong biologic
efﬁcacy. The concept of linking an antibody to a drug is not
new; however, the majority of conjugates made have used
toxins to eliminate cancer cells. In contrast, we use curcumin,
which has been extensively shown in preclinical studies to be
safe, demonstrating selectivity toward cancerous cells.4,5 In
our approach, we potentiate the anticancer efﬁcacy of a compound from a dietary plant, and this strategy offers the possibility of having fewer side effects while maintaining potent
anticancer activity of the agent.
The current mainstream of brain cancer therapy consists
of tumor resection followed by radiation and chemotherapy.

Cancer Therapy

Figure 5. Intratumor adduct infusion followed by peripheral curcumin injection reduces tumor load, prolongs survival and rescues mice.
GL261 cells (105) were implanted in each mouse on Day 1 to form the tumor. Sixteen picomoles of CD68 Ab-linked curcumin (CDC) in 5 ml
PBS per injection (adduct) was infused on Days 13 and 15. (a–d) Three mice were used in each of two groups, one (control) receiving the
CD68 antibody and the other receiving intratumor infusions of the adduct. Two intratumor injections of adduct every 72 hr followed by infusion of 200 ml of 667 mM in PBS plus 3% DMSO (curcumin) per tail-vein injection once every week until death. (e–g) Eight mice were used
in each of two groups. Four intratumor infusions of 30 pmol CDC per mouse (from Day 8, every 72 hr), followed by tail-vein infusions of curcumin (667 mM) every 72 hr. (e) An H&E-stained control brain not receiving the adduct showing widespread degeneration due to glioblastoma. (f) Of the mice that remained healthy and normal (two) one was sacrificed 100 days after implantation of GL261 cells. The brain
section shows the presence of scar tissue at the original site of tumor [enlarged view shown in (h)]. (g) Kaplan–Meier analysis shows a dramatic increase in survival in mice receiving adduct infusion into the tumor followed by curcumin infusion into the tail vein. [Color figure can
be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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The most common chemotherapeutic agent used for brain
cancer treatment is an oral alkylating agent, temozolomide
(Temodar), which crosses the blood–brain barrier but also
produces major side effects.23 Additionally, radiotherapy and
chemotherapy can increase extracellular glutamate, which is
converted into glutamine and consumed as fuel by brain
tumor cells (glioblastoma).24 Our approach of intracranial
drug delivery is feasible as intracranial surgery is the ﬁrst
step taken in brain tumor therapy.
In a clinical setting, repeated access to the intracranial cavity
could be accomplished via an intracranial shunt. Insertions of
shunts to drain cerebrospinal ﬂuid from the brain are done
and can be maintained for long periods of time safely. This
provides an opportunity for drug administration. At the outset,
the intracranial delivery of targeted curcumin may raise many
questions; however, clinical experience supporting this approach
is possible. Intracranial delivery of proteins and peptides has
been used as a therapy for neurodegenerative diseases.25 Our
study reports intracranial delivery of the trophic factor GDNF
into the dorsal putamen, which resulted in improved motor
function in advanced Parkinson’s disease patients. In cancer
therapy, bevacizumab (Avastin) is a humanized monoclonal
antibody that inhibits vascular endothelial growth factor. It has
been used via intra-arterial application to treat brain cancer
patients.26 Selective intra-arterial cerebral infusion techniques
use a catheter, which is inserted into the femoral artery and
passes to the carotid artery. A separate microcatheter inserted
via the femoral catheter is then used to selectively explore the
vessels of interest.26 Bevacizumab has been delivered using
microcatheters into the blood vessels inside the brain close to
the site of the tumor in brain tumor patients.27
Such reports provide additional information on alternate
delivery of proteins, which are often blocked from brain
entry by the blood–brain barrier. These proteins could be
made to enter the brain by the use of mannitol that transiently opens the blood–brain barrier (as used for the delivery
of bevacizumab, when delivered peripherally). We also
understand that antibodies developed in other animals

cannot be used in humans. Thus, advancement into the clinic
would require the use of humanized (chimeric) mouse monoclonal antibodies and also human antibodies developed using
transgenic mice and phage display.10,28–31
Although antibody drug conjugates are very promising
and there are decades of preclinical and clinical studies that
document their use, to date there are only four FDAapproved drugs. Of these, trastuzumab emtansine (T-DM1;
KadcyclaTM) is the most recently approved antibody. Trastuzumab (HerceptinTM) targets HER2, which is overexpressed
on cancer cells of various types such as breast and ovarian
cancer. This monoclonal antibody is conjugated with a maytasanoid, a chemical derivative of a plant compound, maytansine. Like curcumin, this compound has been demonstrated
to be safe and very potent in preclinical studies, but clinical
trials were unsuccessful in demonstrating efﬁcacy. This
included 35 tumor types in more than 800 patients.32 Nonetheless, these tests with the trastuzumab maytasanoid conjugate demonstrated that enhanced tissue delivery of targeted
drugs could be achieved with current technology. Essential to
this approach is the identiﬁcation of a suitable target and the
identiﬁcation of a selective anticancer conjugate. Our study
establishes CD68 as a promising marker to target glioblastoma. We have developed a CDC that is highly effective in
eliminating human glioblastoma cells U87MG and T98G at a
low nanomolar range of IC50. We show that this conjugate
is also effective in our in vivo model and we present data
that targeted curcumin, which is effective and can overcome
the limitations of poor bioavailability of curcuminoids. Furthermore, we present a possible therapeutic approach to treat
a deadly form of brain cancer by using targeted therapy.
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